Stockwinners Market Radar for May 17, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT OpGen trading halted, news pending

19:50 EDT Blue Star Foods Corp trading halted, news pending

18:34 EDT Verizon to waive some fees in storm affected areas in Texas, Louisiana - To help residents in Texas and Louisiana impacted by the recent storms and long-expected recovery, Verizon is waiving postpaid domestic call/text/data usage incurred from May 17 - May 23. This will bring relief to the thousands of customers who are relying on their mobile devices more than ever, and especially during this challenging time. The waiver applies to all postpaid consumer customers, small business customers and Verizon Prepaid customers in the following Louisiana parishes: Allen, Beauregard, Catahoula and St. John the Baptist; and the following Texas counties: Harris, Jasper, San Jacinto and Waller. For prepaid customers using Straight Talk, Tracfone, Total by Verizon, Simple Mobile, Walmart Family Mobile, Net10, GoSmart, and Page Plus, we are extending service end dates to May 23, 2024. Customers do not have to take any action to take advantage of the offer. Any overages for those whose billing cycles have already closed will be automatically credited back.

17:16 EDT HCA Healthcare SVP Torres sells 1,863 common shares - In a regulatory filing, HCA Healthcare senior VP Kathryn Torres disclosed the sale of 1,863 common shares of the company on May 15 at a price of $326.1799 per share.

17:12 EDT Lockheed Martin awarded $756.81M Army contract modification - Lockheed Martin was awarded a $756.81M modification to a contract for Long Range Hypersonic Weapon ground support equipment. Work will be performed in Huntsville, Alabama, with an estimated completion date of February 28, 2028. FY23 missile procurement, Army funds in the amount of $275.27M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:01 EDT BioLineRx receives Nasdaq minimum bid price notification - BioLineRx announced that it has received a notification letter from the Nasdaq Stock Market LLC. The letter notifies the company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the company's American Depositary Shares listed on the Nasdaq was below $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of USD $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the company's Nasdaq listing or the trading of its ADSs, and during the grace period, as may be extended, the company's ADSs will continue to trade on the Nasdaq under the symbol "BLRX".

16:35 EDT Medtronic reports 'positive' results from SPHERE Per-AF study - Medtronic announced positive results demonstrating excellent safety and efficacy of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one pulsed field and radiofrequency ablation and high density mapping catheter for the treatment of persistent atrial fibrillation. The SPHERE Per-AF study, a U.S. FDA Investigational Device Exemption pivotal trial, compared Sphere-9 to the conventional Thermocool SmartTouch SF radiofrequency ablation catheter with the Carto 3 System. Findings were presented as late-breaking clinical data at the Heart Rhythm Society 2024 Annual Meeting and simultaneously published in Nature Medicine.

16:21 EDT Polestar Automotive receives noncompliance notification from Nasdaq - Polestar announced that, as a consequence of not having filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, the company has received a deficiency notice from Nasdaq confirming that it is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic financial reports with the U.S. Securities and Exchange Commission.

16:15 EDT Sylvamo raises quarterly dividend 50% to 45c per share - Sylvamo's board of directors declared a quarterly dividend of 45c per share for the period of July 1, 2024, to Sept. 30, 2024. The dividend is payable July 29, 2024, to holders of record at the close of business July 8, 2024. "I'm pleased our board approved increasing our quarterly dividend to 45 cents per share. This is the third increase in the last two years, highlighting our commitment to return substantial cash to shareowners," said Jean-Michel Ribieras, chairman and chief executive officer. "We remain confident in our future and motivated by the opportunities that lie ahead." The quarterly dividend is increasing 50% from 30c per share to 45c per share.

16:07 EDT Realty Income increases monthly dividend 2.1% to 26.25c per share - Realty Income announced it has declared an increase in the company's common stock monthly cash dividend to 26.25 per share from 25.7c per share. The dividend is payable on June 14 to stockholders of record as of June 3. This is the 125th dividend increase since Realty Income's listing on the NYSE in 1994.

15:54 EDT ISS urges Gildan Activewear holders to vote the GOLD proxy card - Browning West, which is a long-term shareholder of Gildan Activewear and beneficially owns approximately 5.0% of the company's outstanding shares, announced that Institutional Shareholder Services has recommended that Gildan shareholders vote to elect all eight of Browning West's highly qualified director candidates on the GOLD Proxy Card at the upcoming Annual Meeting of Shareholders on May 28. Notably, ISS recommended shareholders WITHHOLD support for all 10 of Gildan's nominees: Timothy Hodgson, Lewis L. Bird, III, Dhaval Buch, Marc Caira, Jane Craighead, Sharon Driscoll, Lynn Loewen, Anne Martin-Vachon, current CEO Vince Tyra, and Les Viner.

14:56 EDT Barnes & Noble Education jumps 17% to 21c after Greenhaven says exploring deal

14:46 EDT Avangrid drops 5% to $35.72 after buyout by Iberdrola

14:25 EDT Avangrid to be acquired by Iberdrola for $35.75 per share in cash - Avangrid (AGR), a member of the group of companies controlled by Iberdrola (IBDRY), announced that it has entered into a definitive agreement under which Iberdrola will acquire the remaining 18.4% of the issued and outstanding shares of common stock of Avangrid that it does not currently own for $35.75 per share in an all-cash transaction. The $35.75 per share price represents a 11.4% premium over the closing price of Avangrid common stock on March 6, the last unaffected trading day prior to Avangrid's announcement of receipt of Iberdrola's unsolicited offer, and a 15.2% premium over the volume-weighted average price of Avangrid common stock over the 30 trading days leading up to the unaffected trading day. Avangrid expects to continue paying regular quarterly cash dividends not to exceed 44c per share through the closing of the transaction, including a pro-rated dividend for any partial quarter prior to the closing. The board of Avangrid, acting on the unanimous recommendation of the Unaffiliated Committee of the Board of Directors that led the consideration of strategic alternatives and the negotiation of the terms of the transaction, unanimously approved the agreement.

12:39 EDT FDA posts tentative approval of Amneal's nimodipine - Reference Link

12:04 EDT DXC Technology falls -16.1% - DXC Technology is down -16.1%, or -$3.21 to $16.67.

12:02 EDT General Dynamics Information Technology awarded $185M task order - General Dynamics Information Technology was awarded a $185M recompete task order to provide cybersecurity services for the Air Force Civil Engineer Center. The task order, awarded by the 772nd Enterprise Sourcing Squadron at Tyndall Air Force Base, Fla., has a one-year base period and four option years.

12:02 EDT Despegar.com rises 14.6% - Despegar.com is up 14.6%, or $1.82 to $14.37.

12:00 EDT Doximity rises 18.1% - Doximity is up 18.1%, or $4.29 to $28.03.

11:41 EDT Medtronic says OmniaSecure met primary safety, effectiveness endpoints - Medtronic announced that its investigational OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability Pivotal Trial. Late breaking results were presented at Heart Rhythm 2024 and simultaneously published in the journal Heart Rhythm. Worldwide, the OmniaSecure defibrillation lead is investigational and not yet approved for sale or distribution. Implantable cardioverter defibrillators are the gold standard for preventing sudden cardiac death. Yet transvenous defibrillator leads, which are thin wires connected to the ICD and threaded through the veins into the heart muscle, remain the weakest point of the system,1 given the harsh environment inside the human body where the lead must remain attached and yet flex with millions of heart contractions over a patient's lifetime. Existing defibrillation leads have a large diameter, which can contribute to venous occlusion or tricuspid valve complications. For patients where an extravascular defibrillator may not be appropriate, Medtronic engineers designed the OmniaSecure defibrillation lead based on the Medtronic SelectSecure Model 3830 pacing lead, which has offered safe and effective treatment to patients for more than 20 years. By beginning with this highly reliable pacing lead and building a larger lead suitable for defibrillation therapy, the Medtronic OmniaSecure lead is the world's smallest transvenous defibrillation lead. Defibrillation testing conducted at device implantation in 119 patients was successful in 97.5% of cases. The study exceeded the prespecified efficacy goal of 88%. At six months, 97.1% of 657 patients with an implant attempt were free from lead-related major complications such as hospitalization, lead fracture, system revision, or death. The study exceeded the prespecified safety performance goal of 90%. There were no lead-related major complications observed between six and 12 months. The LEADR Pivotal trial is a prospective, multicenter, single-arm, non-randomized, global clinical study that assessed the safety and effectiveness of the Medtronic OmniaSecure defibrillation lead when placed at traditional locations in the right ventricle to achieve defibrillation, sensing, pacing and cardioversion in patients at risk of sudden cardiac death. The study enrolled 675 patients at 45 sites in 17 countries in North America, Europe, Asia, and Australia. The lead demonstrated reliable performance with zero study lead fractures through an average follow up of 12.7+/-4.8 months. Medtronic developed and validated an in-vitro model that accurately predicts lead reliability out to 10 years,2 and then applied that model within the study to predict a fracture-free survival of 99.9% at two years for the investigational OmniaSecure lead. The lead also demonstrated a 97.9% implant success rate, and stable electricals through 12 months. Nearly 12% of patients in the study received appropriate therapy for dangerously fast ventricular arrhythmias by 14.0+/-5.0 months. ATP terminated 74.9% of episodes, preventing a shock in 49 patients. Medtronic plans to present additional reliability model results from the LEADR study in the coming months.

11:07 EDT Chemed CEO McNamara sells 4,000 common shares - In a regulatory filing, Chemed president and CEO Kevin McNamara disclosed the sale of 4,000 common shares of the company on May 16 at a price of $567.54 per share.

11:04 EDT Jiade Ltd trading halted, volatility trading pause

10:15 EDT Duke Energy Carolinas reaches settlement agreement in rate review request - Duke Energy Carolinas has reached a settlement agreement with almost all parties, including certain consumer, environmental and industrial groups in South Carolina, for its rate review request filed in January of this year - the first such request by the company since 2018. If the agreement is approved by the Public Service Commission of South Carolina, the total increase will be approximately $240M, the company said in a statement.

10:05 EDT Qilian International to reduce investment in oxytetracycline sector - The company said, "In the past two years, Qilian International Holdings Group Limited has encountered significant challenges stemming from the continuous shrinkage in market demand for its oxytetracycline products, coupled with a persistent decline in market prices and escalating environmental protection standards. These factors have collectively led to a substantial increase in the production and operational costs for Qilian International, consequently impairing the profitability of the oxytetracycline industry. In response to these challenges and in an effort to optimize resource allocation and enhance the company's overall efficiency, Qilian International is planning to reorient its industrial strategy in accordance with the prevailing market conditions and its long-term development objectives." Firstly, Qilian International will reduce its investment in the oxytetracycline sector. The company plans to substantially decrease its capital allocation to the oxytetracycline industry, aiming to mitigate production and operational costs as well as to manage business risks more effectively. Secondly, the company intends to bolster its investment in the heparin sodium sector. Recognized for its critical role as a biomedical raw material, heparin sodium offers extensive application prospects and a promising market outlook within the medical field. Qilian International is committed to significantly enhancing its investment in the research and development, production, and market development of heparin sodium. This strategic move is designed to refine the production techniques and expand the scale of heparin sodium production, thereby addressing the escalating market demands. Thirdly, the company plans to develop a series of licorice products. Qilian International will closely monitor market trends and augment its investment in the research, production, and marketing of licorice-based products, including licorice extract, fluid extract, and compound licorice lozenges. This strategic expansion is intended to broaden the company's market share and enhance profitability. The fourth is to invest in the financial field and software development. With the rapid development of financial technology, the development of financial products and software in the financial field has become a new growth point. The company will actively seize the opportunity to invest appropriately in financial products in the financial field, and gradually increase investment in software development to promote the diversified development of the company.

10:03 EDT Doximity rises 19.3% - Doximity is up 19.3%, or $4.58 to $28.32.

10:02 EDT Kuke Music rises 20.8% - Kuke Music is up 20.8%, or 64c to $3.74.

10:01 EDT DXC Technology falls -17.8% - DXC Technology is down -17.8%, or -$3.53 to $16.35.

09:51 EDT a.k.a. Brands falls -5.6% - a.k.a. Brands is down -5.6%, or -$1.47 to $24.74.

09:50 EDT GameStop falls -23.5% - GameStop is down -23.5%, or -$6.50 to $21.17.

09:48 EDT Despegar.com rises 13.6% - Despegar.com is up 13.6%, or $1.71 to $14.25.

09:43 EDT Rent the Runway trading resumes

09:33 EDT Rent the Runway trading halted, volatility trading pause

09:12 EDT Lexaria Bioscience begins dosing in comprehensive GLP-1 animal study - Lexaria Bioscience announces that dosing has begun in the 12-week animal study WEIGHT-A24-1 to model diabetes treatment and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol, alone and in combination in diabetic preconditioned rats. Each arm of the Study will be dosed for a 12-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous similar animal studies. The Study will also include a comprehensive battery of liver and kidney function testing and blood chemistry analyses.

09:09 EDT Olo announces expanded partnership with Tray - Olo announced an expanded partnership with Tray, a Point of Sale and restaurant management platform geared toward Enterprise restaurants, to offer Olo Pay card-present payment processing via POS and an integration with the Olo Engage product suite. Together the two companies will strengthen their joint value proposition by expanding the Olo Order integration to include automated menu synchronization. Adding to the solution, Tray will activate the integration with the Olo Order Ready AI, a solution that leverages machine-learning to generate accurate ready times for both guests and third-party delivery providers.

09:07 EDT BuzzFeed reconfigures compensation model - BuzzFeed announced its go-forward model for employee equity compensation and incentives. BuzzFeed founder and CEO Jonah Peretti is taking the majority of his compensation as a stock-based package-at the money options-and removing the bulk of his cash based-compensation. The company is also extending stock incentives to senior executives across the organization. The move provides stock options with a strike price at the current value, further aligning the leadership team with the interests of shareholders.

09:05 EDT Trupanion comments on rate filing approval in California - Trupanion provided the following update on its rate filing approval status in California. The California Department of Insurance approved a 29% rate increase, which is in addition to its previously approved 12% rate increase in June of 2023. The new rate will go into effect during late July 2024. The rising cost of veterinary care amplifies the need for Trupanion to price correctly. Given the financial impact inflation has had on veterinary practices in California since 2022, this new rate will bring California residents more in line with those rising costs. Trupanion is excited to continue to support pet parents and the veterinary community in California.

09:04 EDT Stellantis announces changes to its leadership team - Stellantis announced the following organizational changes, effective June 1, 2024. Christine Feuell is appointed Ram brand CEO in addition to her current responsibility as Chrysler brand CEO, replacing Timothy Kuniskis who has decided to retire after nearly 32 years with the Company. Matt McAlear is appointed Dodge brand CEO, replacing Timothy Kuniskis. Matt will become a member of the Top Executive Team.

08:54 EDT Wipro COO Amit Choudhary to step down, Sanjeev Jain to succeed - Wipro announced the appointment of Sanjeev Jain as the COO effective immediately. Sanjeev succeeds Amit Choudhary, who is stepping down to pursue opportunities outside the organization. Sanjeev will report to Srinivas Pallia and will continue to be a member of Wipro's executive committee. Sanjeev joined Wipro in 2023 as the Global Head of Business Operations. He brings over 30 years of experience in leading large, diverse teams, scaling up global operations, and deploying Lean Six Sigma and design thinking principles to drive operational excellence and business transformation.

08:50 EDT First Bancshares to transfer common stock lifting to NYSE - First Bancshares announced that it is transferring the listing of its common stock to the NYSE from Nasdaq. The First Bancshares' common stock is expected to begin trading on the NYSE on Thursday, May 30, under the ticker symbol of "FBMS." The First Bancshares expects its common stock to continue to trade on Nasdaq until the close of the market on May 29.

08:37 EDT Dermata Therapeutics announces exercise of warrants for $2.66M - Dermata Therapeutics announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company's common stock, having exercise prices of $9.7665 and $32.40 per share, issued by Dermata in November 2023 and May 2023 at a reduced exercise price of $5.16 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 and on Form S-1. The closing of the offering is expected to occur on or about May 21, 2024, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, Dermata will issue new unregistered Series A warrants to purchase up to 601,174 shares of common stock and new Series B warrants to purchase up to 431,498 shares of common stock. The new warrants will have an exercise price of $4.91 per share, will be exercisable immediately upon issuance and have a term equal to five and one-half years from the date of issuance, with respect to Series A warrants, and 24 months from the date of issuance, with respect to Series B warrants. The gross proceeds to Dermata from the exercise of the warrants are expected to be approximately $2.66 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to the Company's technologies, licensing activities related to the Company's current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.

08:35 EDT Bannix Acquisition announces monthly extension to complete business combination - Bannix Acquisition Corp. board of directors has decided to extend the date by which Bannix must consummate an initial business combination from May 14, 2024 for an additional month, to June 14, 2024. As previously disclosed, at an annual meeting of its stockholders held on March 8, 2024, Bannix' stockholders voted in favor of a proposal to amend Bannix's Amended and Restated Certificate of Incorporation to provide Bannix with the right to extend the Deadline Date up to six times for an additional one month each time until September 14, 2024. Also as previously announced, if an Extension is implemented, the sponsor of Bannix, Instant Fame, or its designees will deposit into the trust account, as a loan, the lesser of $25,000 and $0.05 for each share that is not redeemed in connection with the annual meeting. On May 15, 2024, the Board, at the request of the Sponsor, decided to implement the fifteen Extension and to extend the Deadline Date for an additional month to June 14, 2024.

08:34 EDT Femasys CEO Kathy-Lee Sepsick meets with White House's OSTP - Femasys announces CEO and Founder Kathy Lee-Sepsick has met with staff from the White House Office of Science and Technology Policy to discuss the President and First Lady's Cancer Moonshot and the Company's FemCerv product. According to The White House, OSTP "works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America's great aspirations." OSTP also supports the Cancer Moonshot, which is focused on mobilizing a national effort to end cancer. During the meeting, Ms. Lee-Sepsick and the OSTP staff discussed the priority actions for the Cancer Moonshot, including important priorities related to cervical cancer. This discussion gave Ms. Lee-Sepsick the opportunity to raise awareness of FemCerv, Femasys' diagnostic tool for the detection of cervical cancer, with a purposeful design that allows for the collection of a complete and uncontaminated sample in a virtually pain-free procedure. Femasys intends to broaden its cancer diagnostic portfolio with an endometrial sampler for uterine cancer in the future. "Meeting with the esteemed Office of Science and Technology Policy was a remarkable experience, where I had the opportunity to discuss our work in cancer diagnosis with our FemCerv product for cervical cancer and other products in development," stated Ms. Lee-Sepsick. "The Cancer Moonshot emphasizes the importance of early detection, and we are excited to explore avenues to collaborate, as we commercialize our diagnostic product that is in line with the Cancer Moonshot's mission to dramatically reduce cervical cancer."

08:32 EDT Femasys CEO Kathy-Lee Sepsick meets with White House's Gender Policy Council - Femasys announces CEO and Founder Kathy Lee-Sepsick has met with staff from the White House Office of Science and Technology Policy to discuss the President and First Lady's Cancer Moonshot and the Company's FemCerv product. According to The White House, OSTP "works to bring that idea to life by harnessing the power of science, technology, and innovation to achieve America's great aspirations." OSTP also supports the Cancer Moonshot, which is focused on mobilizing a national effort to end cancer. During the meeting, Ms. Lee-Sepsick and the OSTP staff discussed the priority actions for the Cancer Moonshot, including important priorities related to cervical cancer. This discussion gave Ms. Lee-Sepsick the opportunity to raise awareness of FemCerv, Femasys' diagnostic tool for the detection of cervical cancer, with a purposeful design that allows for the collection of a complete and uncontaminated sample in a virtually pain-free procedure. Femasys intends to broaden its cancer diagnostic portfolio with an endometrial sampler for uterine cancer in the future. "Meeting with the esteemed Office of Science and Technology Policy was a remarkable experience, where I had the opportunity to discuss our work in cancer diagnosis with our FemCerv product for cervical cancer and other products in development," stated Ms. Lee-Sepsick. "The Cancer Moonshot emphasizes the importance of early detection, and we are excited to explore avenues to collaborate, as we commercialize our diagnostic product that is in line with the Cancer Moonshot's mission to dramatically reduce cervical cancer."

08:31 EDT Surf Air Mobility begins commuter service to ORD from LAF - Surf Air Mobility officially began scheduled commuter service on Wednesday, May 15, with a flight between West Lafayette / Purdue University Airport, or LAF, and Chicago O'Hare Airport, or ORD.

08:22 EDT Immunome promotes Max Rosett to CFO - Immunome announced the promotion of Max Rosett to CFO, effective May 9. Rosett most recently held the role of Executive VP, operations, in addition to serving as Immunome's interim CFO since January.

08:15 EDT Eagle Materials to invest $430M to modernize Wyoming cement plant - Eagle Materials announced plans to modernize and expand its Laramie, Wyoming cement plant and related distribution facilities, which provide cement to several markets, including the northern Colorado area, Nebraska, Utah and Wyoming. The modernized plant and an additional cement distribution facility in northern Colorado will incorporate technology maximizing operating efficiencies. The expansion will increase the plant's annual manufacturing capacity by 50% to approximately 1.2M tons of cement and is expected to reduce manufacturing costs by approximately 25%. Expected cost reductions from the modern kiln line will be generated by replacing the use of solid fuels with lower cost alternative fuels and natural gas, simplified maintenance programs, and improved operating efficiencies. Additionally, the CO2 intensity from the Laramie, Wyoming facility is expected to decline by nearly 20% once the project is complete. The project investment, which includes an additional distribution facility in northern Colorado, is estimated to be approximately $430M. The existing plant, which became operational in 1927, has an annual capacity of 800,000 tons of cement. Planning for the project has been completed, primary regulatory approvals have been received and construction is expected to begin immediately with startup scheduled for the second half of calendar year 2026. With this expansion, Eagle re-emphasizes its commitment to be the cement supplier of choice in the Mountain Region, including the key cities of Denver and Salt Lake City, meeting the expected increase in demand for cement more broadly and to reduce the intensity of carbon emissions from its facilities.

08:10 EDT Achieve Life Sciences announces data from Phase 2 ORCA-V1 trial - Achieve Life Sciences announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine, SGIM, Annual Meeting being held in Boston, MA. Dr. Nancy Rigotti, ORCA-V1 Principal Investigator and Professor of Medicine at Harvard Medical School, and Director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, will present data from the Phase 2 ORCA-V1 trial. This study explored the efficacy and safety of cytisinicline in adult smokers seeking to quit nicotine e-cigarettes. In the study, treatment with cytisinicline more than doubled the likelihood of quitting compared to placebo.

08:07 EDT Marti Technologies CFO Cem Yasar Ozey departs, Oguz Erkan succeeds - Marti (MRTI) announced that it has appointed Oguz Erkan as its new CFO, effective May 17. Oguz Erkan replaces the company's former CFO, Cem Yasar Ozey. Erkan has a 22-year career holding roles in finance, strategy, and project management across various industries. Preceding his appointment at Marti, he served as the Country CFO of GlaxoSmithKline (GSK) Turkiye.

08:05 EDT American Rebel to exhibit at NRA Annual Meeting in Texas - American Rebel Holdings will exhibit in booth #4417 at the 2024 NRA Annual Meeting at the Kay Bailey Hutchison Convention Center in Dallas, Texas May 17 - 19. The Exhibit Hall is open all three days and will showcase over 14 acres of the latest guns and gear from the most popular companies in the industry. "We always look forward to showcasing our safes and concealed carry apparel at the NRA Annual Meeting," said American Rebel CEO Andy Ross. "But this year we can't wait to introduce America's Patriotic, God-fearing, Constitution-loving, National Anthem-singing, stand your ground beer to 75,000 or so like-minded patriots attending this year's Annual Meeting. We sell quite a few safes and concealed carry backpacks and apparel out of the booth every year, and this year we'll tell everyone about American Rebel Light Beer and hand out some promotional items to support our beer launch."

08:01 EDT MingZhu Logistics partners with Carbonomi Group on logistics network - MingZhu Logistics announced it will partner with Carbonomi Trust, aninvestor in energy transition-related technologies and companies including satellite-based communication and IoT infrastructure. The strategic partners will leverage their respective expertise and resources to build a high-performance satellite-based intelligent logistics network primarily targeting business and enterprise users, with fixed site and mobile coverage.

07:47 EDT Tilray announces ATM program to fund acquisitions, accelerate expansion - Tilray Brands has filed a prospectus supplement with the U.S. Securities and Exchange Commission, under which it may offer and sell shares of its common stock having an aggregate offering value of up to $250 million from time to time through an at-the-market equity program. The Company has entered into an equity distribution agreement with TD Securities and Jefferies. Pursuant to the equity distribution agreement, TD Securities and Jefferies may sell the Company's Common Stock in transactions that are deemed an "at-the-market offering" defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Global Select Market. The timing and amount of any such sales will be determined by a variety of factors considered by the Company. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices. As a result, sales prices may vary. The Company currently intends to use the net proceeds from the ATM Program, if any, to fund strategic and accretive acquisitions or investments in businesses, including potential acquisitions of assets in the U.S. and internationally in order to capitalize on expected regulatory advancements or expansion opportunities. The Company does not currently intend to use the net proceeds from the ATM Program for general working capital purposes.

07:37 EDT Nextech3D.AI announces new deals, renewals in 3D modeling business - Nextech3D.AI announced a series of new deals and renewals for its 3D modeling business. To date, the company has delivered over 70,000 models to customers across various industries and expects significant growth in 2024 and beyond, driven by Amazon's expanding platform for 3D models and AR experiences. The company is also extending its market reach into sectors like brake pads, calipers, crossbows, Bosch power tools, pallet jacks, and more.

07:36 EDT GameStop sinks 10% to $24.88 after Q1 sales outlook

07:31 EDT Cytokinetics hosts CLIMB Research Symposium - Cytokinetics announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium, May 17th, 2024 at the Mission Bay Conference Center in San Francisco. "We are proud to convene the CLIMB Research Symposium, a unique forum for the muscle biology community, including academic researchers and students, to engage in scientific discussion and share innovative research," said Fady I. Malik, EVP of Research & Development. "As pioneers in the therapeutic applications of muscle biology, we are driven to continuously push the boundaries in the field and advance the understanding and potential treatment of muscle-related diseases and disorders. Through collaboration with academia and industry, we are committed to driving transformative progress to shape the future of muscle biology." CLIMB is a one-day research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the understanding and treatment of muscle-related diseases and disorders.

07:16 EDT Telix Pharmaceuticals files registration statement for proposed U.S. IPO - Telix Pharmaceuticals has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company's ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol "TLX". The number of ordinary shares to be represented by each ADS, the number of ADSs to be offered and the price per ADS for the proposed Offering have not yet been determined. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed. Jefferies, Morgan Stanley, Truist Securities and William Blair will act as joint book-running managers for the proposed Offering.

07:05 EDT Xortx Therapeutics reprices balance of warrants issued in connection with IPO - XORTX Therapeutics announces that further to its press releases of March 11 and April 30, 2024, the Company has received TSX Venture Exchange approval to amend the terms of the balance of outstanding common share purchase warrants that were issued on October 15, 2021. Reference is made to the Company's press release of October 7, 2022 wherein the Company indicated that the Warrants had been repriced in connection with the October 7, 2022 private placement, however that process was not completed at the time. The re-pricing approval received affects an original 910,000 warrants. The Warrants had an original exercise price of $42.93. The TSXV has now approved an amended exercise price of $5.00 and the acceleration provision. If the volume weighted average price for the Company's common shares on TSXV is greater than $6.50 per common share for a period of ten consecutive trading days, then the Company may give notice to the Holders of the Warrant by way of a news release notifying such Holder that the Warrants must be exercised within thirty calendar days from the date of delivery of such Notice, otherwise the Warrants will expire at 4:30 p.m. on the 30th day after the date of delivery of the Notice. Notwithstanding anything herein to the contrary, the Forced Conversion Right shall only be available to the Company on or after such time in which such forced exercise of the Warrants will result in the issuance of Free Trading Shares to the Holder.

07:03 EDT Village Farms 'applauds' move toward U.S. marijuana rescheduling - Village Farms International applauds the U.S. Department of Justice's historic decision to pursue federal rescheduling of marijuana for medical purposes to Schedule III from Schedule I under the Controlled Substances Act. The Rescheduling Proposal starts a 60-day period for public comment. "We are encouraged by this continued regulatory progress and are actively evaluating multiple parallel strategies that may enable Village Farms to enter the legal U.S. marijuana market. All options are expected to leverage our unmatched cannabis success in Canada, using our advantage as one of the largest and highest quality greenhouse cannabis operations in the world. We will continue to monitor regulatory and other developments that may result from the proposed rescheduling and look forward to determining the right path forward for the Company and our shareholders to fully capitalize on the U.S. marijuana opportunity," said Michael DeGiglio, President and CEO.

06:45 EDT nVent Electric announces $500M share repurchase program - nVent Electric announced that its Board of Directors has approved a 3-year share repurchase program pursuant to which the company may repurchase up to $500M of nVent shares. The program begins on July 23, 2024, upon the expiration of nVent's current share repurchase program. As of March 31, 2024, the company had approximately 166M common shares outstanding.

06:31 EDT Ault Inc.'s Sentinum announces 89 Bitcoin mined in April - Ault Alliance announced that its wholly owned subsidiary, Sentinum, mined approximately 89 Bitcoin in April. Of this total, approximately 46 Bitcoin were mined at Sentinum's data center in Michigan, with the remaining approximately 43 Bitcoin having been mined using the miners hosted by Core Scientific.

05:58 EDT Siemens agrees to sell Innomotics to KPS for EUR 3.5B - The Managing Board and Supervisory Board of Siemens AG have approved the sale of Innomotics, an electric motors and large drives company, to KPS Capital Partners, LP. The contracting parties have signed a corresponding agreement. The purchase price is EUR 3.5B. The sale to KPS is expected to close in the first half of fiscal 2025 and is subject to customary foreign-investment and merger control approvals. "By selling Innomotics to KPS, I am pleased that we have made further significant progress in optimizing our portfolio. The search for the best new owner has been successful," said Ralf P. Thomas, Chief Financial Officer of Siemens AG. "This decision gives customers and the people who work at Innomotics clarity and paves Innomotics' way to extensive opportunities for further successful business development. In the future, Siemens and its shareholders will benefit even more from combining the real and the digital worlds." Reference Link

05:14 EDT Philips to present new retrospective cardiac care solutions study results - Royal Philips is presenting new retrospective study results demonstrating the clinical and economic benefits of Philips' AI-powered cardiac care solutions at the Heart Rhythm Annual Meeting in Boston. Findings from the three studies highlight the central role mobile cardiac monitoring technology plays in supporting early detection of adverse cardiac events and enabling potentially life-saving interventions for patients, while helping to reduce readmissions and lower costs. Recently published in The Journal of Comparative Effectiveness Research, a Philips study compares the clinical and economic outcomes of using the Philips mobile cardiac outpatient telemetry (MCOT) wearable ECG sensor with implantable loop recorders (ILRs) in stroke patients to determine how cardiac remote monitoring technology impacts current standards of care. This study analyzed the eighteen months following a stroke event and found that when MCOT was used instead of ILR for post-discharge monitoring: Patients experienced significantly lower readmissions (30.2% in the MCOT-monitored group compared to 35.4% in the ILR group); Average cost over an 18-month period following the stroke event was reduced by USD 27,429; Emergency department utilization was significantly lower; Patients with complications and comorbidities from the index stroke experienced a higher rate of survival.

05:04 EDT Aurora Mobile, Zeekr enter strategic partnership - Aurora Mobile (JG) announced that it has entered into a strategic partnership with Chinese electric vehicle manufacturer Zeekr (ZK). Leveraging its JPush push notification service, Aurora Mobile will help Zeekr optimize the efficiency and effectiveness of user reach and engagement through the Zeekr app and deepen the connection with its users.